Heart failure & cardiomyopathies
Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction
Authors' conclusion
Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) in the EMPHASIS-HF trial
- Participants
- 975 / 769 / 988
- Comparison
- Eplerenone vs placebo, by HFrEF duration
- <1 yearn = 975
- 1 to <5 yearsn = 769
- ≥5 yearsn = 988
- Primary endpoint
- HF hospitalization or CV death
Methodological detailssubgroup analysis by HFrEF duration
- Subgroup analysis by HFrEF duration
Primary result
As reported in the abstract
HF hospitalization or CV death, eplerenone vs placebo, by HFrEF duration
Eplerenone vs PlaceboHazard ratio (95% CI)P value
<1 year
0.57(0.42–0.79)
1 to <5 years
0.81(0.60–1.10)
≥5 years
0.61(0.48–0.78)
P = 0.24for interaction- Benefit of eplerenone consistent across heart failure (HF) duration
- P for interaction = 0.24
Further findings
Baseline characteristics by HF duration
- Longer-standing HF: older, more CV and non-CV comorbidities
Original publication
Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →